Top Medtech and Healthtech Companies in 2026: Where the Growth Actually Is

I wrote a piece earlier this year ranking the best medical device companies in 2026, and it struck a nerve. Tens of thousands of people read it. A lot of the feedback was some version of: "You covered the traditional device companies, but what about the companies blurring the line between devices, software, and services? The ones that don't fit neatly into 'medical device' but are reshaping how healthcare is delivered?"

Fair point. The medtech and healthtech landscape in 2026 is broader than traditional device companies, and some of the most interesting growth stories are happening at the intersection of hardware, software, and clinical services. These are the companies I find most worth paying attention to right now.

A caveat before I start: this isn't a ranking by revenue or market cap. It's organized by the categories where I see the most momentum, based on my own conversations and observations. I'm going to miss companies that deserve to be here. If your company isn't on this list, it doesn't mean I think it's irrelevant; it means I don't have enough direct exposure to write about it honestly.

Medtech/Healthtech Category Snapshot: 2026

AI-Powered Diagnostics: The Category That's Finally Real

I've been skeptical about AI in healthcare for years. The gap between "promising research" and "product a hospital will actually buy and use" has been enormous. But in 2026, a handful of diagnostic AI companies have crossed that gap. They have FDA clearances. They have reimbursement. They have hospitals renewing contracts after year one, which means the product is actually being used, not just purchased.

The companies I'm watching most closely are in radiology and pathology, where AI has a clear value proposition: reading images faster and more consistently than human clinicians alone. I'm deliberately not naming specific companies here because my visibility into their internal operations and commercial traction varies, and I don't want to endorse companies I can't speak about with confidence. What I will say is that the companies succeeding in this space share three traits.

They got FDA clearance early and built a clinical evidence base. Hospitals don't buy AI tools based on pitch decks. They buy based on published clinical validation and regulatory clearance. The FDA's public database of AI/ML-enabled medical devices now lists over 900 cleared products; even two years ago that number was closer to 500. The companies that invested in clinical trials and FDA submissions years ago are reaping the commercial benefit now.

They solved the integration problem. An AI diagnostic tool that requires a radiologist to log into a separate system, upload images, and check results in a different workflow is dead on arrival. The companies winning are the ones whose tools are embedded directly in the radiology PACS system. The radiologist doesn't change their workflow; the AI just adds a layer of analysis. That distinction matters more than the quality of the algorithm.

They focused on reimbursement from day one. An AI tool with no CPT code and no reimbursement pathway is a research project, not a business. The companies that engaged with CMS early, worked through the AMA CPT process, and can tell a hospital "this is how you get paid for using our tool" are the ones generating recurring revenue.

For reps, the selling environment in diagnostic AI is unlike traditional device sales. You're selling to laboratory directors, radiology department heads, and hospital CIOs. The conversation is about workflow efficiency, accuracy improvements, and economic return. If you're interested in this space, our healthcare software sales guide covers the skill set it requires.

Remote Patient Monitoring: Reimbursement Unlocked the Market

Remote patient monitoring (RPM) technology has existed for a decade. The companies that made connected blood pressure cuffs, glucose monitors, and pulse oximeters were always looking for a business model. The technology worked. The reimbursement didn't.

That changed. CMS has been steadily expanding RPM reimbursement codes, and in 2025-2026 the revenue model finally works for health systems. The CMS RPM billing codes (CPT 99453, 99454, 99457, 99458) allow a practice to bill $150-$200 per patient per month for RPM services when the monitoring, data review, and clinical intervention are properly documented. At scale, that's meaningful revenue.

The companies capitalizing on this aren't necessarily the ones making the hardware. The real value is in the platform that aggregates the data, alerts clinicians to concerning trends, and documents the billing-eligible activities. The hardware is increasingly commoditized; the platform and the clinical workflow integration are the differentiators.

What makes RPM interesting from a sales perspective is that the buyer is often a physician practice or a health system's population health team, not a traditional hospital IT department. The sales cycle is shorter than enterprise software (typically 2-4 months rather than 6-18 months), and the ROI pitch is straightforward: "Here's how much Medicare will pay you per patient per month. Here's our platform cost. The margin is positive from month one."

I know reps who moved from traditional device sales to RPM platform sales and describe it as a different kind of work. Less OR time, more conversations about practice economics and population health strategy. The compensation structure tends to be SaaS-like: lower base than surgical device sales, but recurring commission on subscription revenue that compounds over time.

Surgical Robotics: Beyond Intuitive

I covered Intuitive Surgical in my device companies piece, and their dominance in surgical robotics is well established. What's changed in 2026 is that the competitive landscape has real entrants, not just press releases.

Medtronic's Hugo system is in clinical use at multiple sites. J&J's Ottava program is progressing. And there are smaller companies, several of them backed by significant venture capital, developing robotic systems for specialties where Intuitive doesn't compete directly: orthopedics, spine, and ENT.

The sales implications are significant. When Intuitive was the only game in town, the selling environment was primarily about maintenance and expansion within the installed base. With real competitors emerging, the market is shifting toward competitive selling. Hospitals are evaluating alternatives. Surgeons are willing to look at new platforms. That creates both opportunity (for the challengers) and threat (for the incumbent).

Reps selling surgical robotics need a different skill set than traditional device sales. These are capital equipment deals with 6-18 month sales cycles. The buyer is the hospital C-suite, not the surgeon (though surgeon advocacy is critical). The conversation includes ROI modeling, utilization projections, service contract terms, and training infrastructure. It's closer to enterprise software sales than to selling implants.

The compensation in surgical robotics reflects the complexity. I've covered the specific numbers in our medical device sales salary guide, but the summary is that base salaries run $100K-$130K with total comp reaching $250K-$350K for experienced reps. The talent pool is genuinely scarce, which is why the comp is where it is.

Digital Therapeutics: Still Finding Its Footing

I want to include digital therapeutics (DTx) because it's a category that generates a lot of discussion, but I'm going to be more cautious here than in the other sections.

DTx companies develop software-based interventions that are FDA-cleared and prescribed by physicians. The category has had a rough few years commercially. Several high-profile DTx companies struggled to gain traction with payers and physicians, and a few went out of business entirely.

The companies still standing have generally pivoted toward clinical areas where the evidence base is strongest (substance use disorders, insomnia, chronic pain management) and where payer reimbursement is available. But adoption remains slow. Physicians are not yet accustomed to prescribing an app, and the infrastructure for digital prescribing is still developing.

I wouldn't recommend DTx as a career destination for someone looking for stability and high compensation in 2026. The market might mature in 2-3 years. Or it might continue to struggle with adoption and reimbursement. I genuinely don't know, and I'm suspicious of anyone who claims certainty about DTx's trajectory right now.

That said, if you're the kind of person who wants to be early in a category that could become very large, and you can tolerate uncertainty and a startup environment, it might be worth a closer look. Just go in with realistic expectations.

Health System Services: The Companies Nobody Talks About

There's a category of company that doesn't get covered in medtech rankings because they're not selling a product. They're selling a service to health systems: revenue cycle management, clinical staffing, physician relations, care navigation, population health analytics.

These companies aren't glamorous. They don't demo well at conferences. But some of them are growing fast because they solve operational problems that every health system has: billing errors, staffing gaps, referral leakage, readmission penalties.

The sales motion is enterprise B2B: long cycles, multiple stakeholders, complex implementations. The compensation is typically lower than specialty device sales but competitive with healthcare software ($80K-$120K base, $150K-$220K total comp). The career path often leads to strategic account management or consulting, which some people find more intellectually engaging than territory-based selling.

I'm including this category because I think it's overlooked by people mapping the medtech/healthtech landscape. The companies making money in healthcare aren't always the ones making devices or software. Sometimes they're the ones fixing the operational problems that prevent health systems from functioning efficiently.

What This Means If You're Hiring

If you're a medtech or healthtech company trying to build a sales team in 2026, the hiring challenge is real across all of these categories. The talent pool for people who can sell technology into healthcare environments is small, and it's getting smaller relative to demand.

The traditional approach, post a job, screen for healthcare experience plus sales skills, interview, offer, takes 3-6 months. During that time, territories are uncovered, launches are delayed, and competitors are hiring from the same pool.

This is why companies across the medtech and healthtech spectrum are increasingly using contract sales professionals to maintain coverage and velocity while they build their permanent teams. An experienced contract rep who understands the healthcare selling environment can be productive in weeks, not months.

MDliaison connects medtech and healthtech companies with pre-vetted sales professionals across medical device, software, and clinical services verticals. If you're building a team or covering a gap, it's worth a conversation.

Where I'd Pay Attention

If someone asked me where the most interesting career opportunities in medtech and healthtech are right now, I'd point to three areas.

Diagnostic AI, because the market is tipping from early adopter to early majority, and the companies that got there first have a meaningful head start.

Remote patient monitoring, because the reimbursement landscape finally supports it and the addressable market is enormous.

And surgical robotics competition, because the entry of real Intuitive competitors is creating a selling environment that rewards aggressive, skilled reps in a way that the Intuitive monopoly never did.

Traditional device sales isn't going away. The top device companies are still hiring aggressively and paying well. But the growth edges of the industry are increasingly at the technology intersection, and that's where I'd want to be if I were starting my career in this space today.

For more on the compensation landscape across these categories and the medical device sales trends shaping the market, we've covered both in detail.

Related Articles:

• Best Medical Device Companies 2026
• Medical Device Sales Salary Guide 2026
• Top Healthcare Software Sales Companies 2026
• Medical Device Sales Trends 2025
• Medical Sales Compensation Benchmarks
• Healthcare Software Sales Jobs Guide